期刊文献+

干扰素-βla配合甲泼尼龙冲击疗法治疗复发缓解型多发性硬化的疗效分析 被引量:3

原文传递
导出
摘要 目的探讨干扰素(IFN)-βla配合甲泼尼龙冲击疗法(MPPT)治疗复发缓解型多发性硬化(RRMS)的疗效。方法回顾性分析74例RRMS患者的临床资料,按治疗方法不同分为观察组(于急性期行MPPT治疗,缓解期给予IFN-βla治疗)和对照组(仅于急性期行MPPT治疗),并进行疗效比较。结果MPPT对急性期RRMS患者有效率在93.2%(69,74),且不良反应较小,治疗后扩展的功能障碍状况量表单项神经功能障碍评分中锥体系功能、膀胱直肠功能、小脑功能、脑干功能、视觉或视神经功能5项评分较治疗前显著减少[(2.31±0.94)分比(3.23±1.10)分、(O.81±0.75)分比(1.74±0.57)分、(2.03±0.86)分比(2.20±0.89)分、(1.34±0.80)分比(1.77±0.59)分、(0.58±0.72)分比(O.66±0.80)分],差异有统计学意义(P〈0.01或〈0.05),感觉功能、大脑或智能功能评分比较差异无统计学意义(P〉0.05)。观察组2年总复发率为40.O%(12/30),对照组为65.9%(29144),两组比较差异有统计学意义(P〈0.05)。结论对于RRMS患者,于急性期给予MPPT治疗,于缓解期给予IFN-βla治疗,既可以在短时间内控制急性期症状,修复神经功能,最大限度减少糖皮质激素的不良反应,又可以有效降低RRMS复发率,是临床工作者较好的选择。
作者 陈勇 黄光祥
出处 《中国医师进修杂志》 2013年第15期67-69,共3页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献8

  • 1Wang KC, Lee CL, Chen SY, et al. Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis. J Interferon Cytokine Res, 2013,33 (2) : 58-64.
  • 2Owens GM, Olvey EL, Skrepnek GH, et al. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm, 2013,19( 1 ) :41-53.
  • 3Foley JF, Zerkowski K, Nair KV. Evidence for long-term use of intramuscular interferon Beta-la: an overview of relapse, disability, and MRI data from selected clinical trials. J Manag Care Pharm, 2013,19(1): 4-15.
  • 4Foley JF, Barnes C J, Nair KV. Emerging methods for evaluating the effectiveness of intramuscular interferon Beta-la for relapsing- remitting multiple sclerosis. J Manag Care Pharm,2013,19 (1): 16-23.
  • 5Collongues N, Vermersch P. Multiple sclerosis spasticity: 'state-of- the-art' questionnaire survey of specialized healthcare professionals. Expert Rev Neurother, 2013,13 ( 3 ) : 21-25.
  • 6Berger T. Multiple sclerosis spasticity daily management: retrospective data from Europe. Expert Rev Neurother,2013,13 (3):3-7.
  • 7Filippi M, Preziosa P, Rocca MA. Vitamin A : yet another player in multiple sclerosis pathogenesis. Expert Rev Clin Immunol, 2013,9 (2):113-115.
  • 8侯玉立,周培斌,刘桂芬.干扰素β治疗复发缓解型多发性硬化疗效分析及安全性评价[J].中国药物与临床,2009,9(1):21-25. 被引量:10

二级参考文献6

  • 1Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committe on clinical trials of new agents in multiple sclerosis. Neurology, 1996,46(4):907-911.
  • 2Poser CM,Paty DW,Scheinberg L,et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol, 1983,13(3):227-231.
  • 3McDonald WI,Compston A,Edan G,et al. Recommended disgnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol, 2001,50:121-127.
  • 4Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983,33 (11): 1444-1452.
  • 5IFN-β Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis.Neruology, 1993, 43(41):655-661.
  • 6Lawrence D, Diane L, Richard A. Intramuscular interferon betala for disease progression in relapsing multiple sclerosis. Ann Neurol, 1996,39:285-294.

共引文献9

同被引文献19

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部